(Reuters) -Ionis Pharmaceuticals said on Tuesday its experimental drug met the main goal of reducing the level of a type of fat in a late-stage trial testing it as a treatment for a rare genetic disorder.
The genetic disorder, known as familial chylomicronemia syndrome (FCS), affects fat metabolism and is characterized by extremely high levels of triglyceride — the most common type of fat in the body.
The drug candidate, olezarsen, showed statistically significant reduction in levels of triglyceride compared to placebo, as well as showed a 100% reduction in inflammation of the pancreas, the company said.
FCS is estimated to occur in 1 in 1-2 million people, according to National Pancreas Foundation.
Ionis said it plans to file a marketing application with the U.S. Food and Drug Administration for olezarsen early next year.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
